Core Viewpoint - The company has announced a cash dividend of 0.06 yuan per share, approved at the 2024 annual general meeting held on May 23, 2025 [1][2]. Dividend Distribution Plan - The dividend distribution is based on the total share capital minus shares held in the company's repurchase account, with a total of 399,441,300 shares eligible for distribution [2][4]. - The total cash dividend to be distributed amounts to 23,966,478.00 yuan (including tax) [2]. - The company will not issue bonus shares or capital reserves, and the distribution will only involve cash dividends [2][4]. Implementation Method - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders registered by the end of the trading day on the record date [5]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date, while those who have not will have their dividends held until they complete the necessary transactions [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.06 yuan per share [8]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the sale of shares [8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld, resulting in a net distribution of 0.054 yuan per share [9].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：(86-28) 6739-8000 传真：(86-28) 6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 差异化分红事项的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发股 份有限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下 简称《公司法》）、《中华人民共和国证券法》《上市公司股份回购规则》（以下简 称《回购规则》）、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 （以下简称《回购股份指引》）等相关法律、法规及规范性文件以及《成都先导 药物开发股份有限公司章程》（以下简称《公司章程》）的有关规定，就公司 2024 年度利润分配涉及的差异化分红相关事项（以下简称"本次差异化分红"）出具 本法律意见书。 为出具本法律意见书，本所审查了公司提供的有关文件及其复印件，并取得 公司向本所作出的如下保证：公司已向本所提供了出具本法律意见书所必须的、 真实、完整的原始书 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-023 成都先导药物开发股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否涉及差异化分红送转：是 每股分配比例 3. 差异化分红方案： （1） 差异化分红方案 每股现金红利0.06元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经成都先导药物开发股份有限公司（以下简称"公司"）2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（公 司回购专用证券账户除外）。 根据公司 2024 年年度股东 ...

成都先导药物开发股份有限公司主营业务是DEL技术相关的药物研发服务，公司的主要服务主要包含 DEL筛选服务,DEL库定制,FBDD/SBDD,新药定制开发,化合物结构知识产权转让及化学合成等其他新药 研发相关服务等。截至报告期末，公司累计已取得138项发明专利及13项软件著作授权，并有300余项境 内外发明专利正在申请中。同时，公司在过去十余年的工作中围绕DEL技术领域进行了大量的研究和探 索性工作，从而积累了大量的技术诀窍，是其它公司和科研单位难以在短期内通过阅读文献和自身研发 而实现的。 6月9日，成都先导今日收盘17.26元，上涨2.31%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到105.26倍，总市值69.16亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.42倍，行业中值44.32倍，成都先导排 名第40位。 股东方面，截至2025年3月31日，成都先导股东户数16254户，较上次增加2538户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入1.07亿元，同比-0.60%；净利润2828.44万元 ...

Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

证券代码：688222 证券简称：成都先导 公告编号：2025-022 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ? 风险提示 本次交易尚处于筹划阶段，交易各方尚未签署正式的交易协议，具体交易方 案仍在商讨论证中，相关事项尚存在不确定性；本次交易需按照相关法律、法规 及公司章程的规定履行必要的决策和审批程序，最终能否实施及实施的具体进度 均具有重大不确定性。 一、本次筹划重大资产重组事项的基本情况 成都先导药物开发股份有限公司（以下简称"公司"）正在筹划以现金方式 受让股权的方式合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"） 约 65%的股权（以下简称"本次交易"）。本次交易完成后，公司将成为标的公司 的控股股东。 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 了《股权收购意向 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-022 风险提示 本次交易尚处于筹划阶段，交易各方尚未签署正式的交易协议，具体交易方 案仍在商讨论证中，相关事项尚存在不确定性；本次交易需按照相关法律、法规 及公司章程的规定履行必要的决策和审批程序，最终能否实施及实施的具体进度 均具有重大不确定性。 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次筹划重大资产重组事项的基本情况 成都先导药物开发股份有限公司（以下简称"公司"）正在筹划以现金方式 受让股权的方式合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"） 约 65%的股权（以下简称"本次交易"）。本次交易完成后，公司将成为标的公司 的控股股东。 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 本次交易尚处于筹划阶 ...

Group 1 - The pharmaceutical sector is experiencing renewed activity, particularly in CRO, innovative drugs, and medical services, with significant gains in related ETFs [1] - The Biopharmaceutical ETF (159859) rose by 1.7%, with trading volume exceeding 50 million yuan, while the Innovative Drug ETF Tianhong (517380) increased by 1.66%, with several constituent stocks rising over 5% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ) and is the largest product in its category, also offering a connecting fund [1] Group 2 - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago and online [2] - The innovative drug sector is highlighted as a key focus for the year, with attention on areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy, alongside domestic pharmaceutical consumption and medical aesthetics [2] - The innovative drug sector is expected to maintain its growth, supported by policy, global competitiveness, and improving fundamentals, with a potential recovery in demand anticipated by 2025 [2]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].